Related Experiment Video
Updated: May 10, 2025
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
2.0K
Alectinib-Loaded Chitosan-Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations
Tha'er Ata1, Israa Al-Ani1, Nida Karameh2
1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Pharmacological and Diagnostic Research Center (PDRC), Al-Ahliyya Amman University, Amman 19328, Jordan.
Pharmaceutics
|April 26, 2025
Summary
Novel chitosan-alginate nanoparticles (ACANPs) significantly enhance Alectinib
Area of Science:
- Nanotechnology
- Pharmaceutical Sciences
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) is a major global health concern.
- Alectinib is an effective ALK inhibitor for NSCLC but suffers from poor solubility and bioavailability.
- Developing advanced drug delivery systems is crucial for improving NSCLC treatment.
Purpose of the Study:
- To develop Alectinib-loaded chitosan-alginate nanoparticles (ACANPs).
- To enhance the solubility, oral bioavailability, and therapeutic efficacy of Alectinib for NSCLC treatment.
Main Methods:
- ACANPs synthesized via a combined solid/oil/water emulsification and ionotropic gelation technique.
- Characterization using FTIR, DSC, DLS, and zeta potential.
- In vitro drug release, cytotoxicity (MTT assay), and pharmacokinetic studies in rats (LC-MS/MS).
Main Results:
- ACANPs achieved ~97% encapsulation efficiency, 161 nm size, and +21 mV zeta potential.
- A threefold increase in Alectinib release from ACANPs over 48 hours.
- Enhanced cytotoxicity and a 78% increase in oral bioavailability in rats.
Conclusions:
- ACANPs significantly improve Alectinib's solubility, efficacy, and oral bioavailability.
- ACANPs represent a promising nanocarrier for improved NSCLC therapy.
- This nanocarrier system holds potential for better patient outcomes in NSCLC treatment.
